ANGO vs DCTH
ANGO: AngioDynamics develops minimally invasive vascular intervention devices for treating peripheral artery disease, thrombosis, and cancer, anchored by its proprietary Auryon laser atherectomy platform. DCTH: Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved HEPZATO kit for uveal melanoma metastases.
Side-by-side fundamentals
| Metric | ANGO | DCTH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.82 | $12.53 | |
| Market cap as of 2026-07-23 | $588M | $433M | |
| P/E as of 2026-07-23 | n/a | 771.04 | |
| PEG as of 2026-07-23 | -2.53 | n/a | |
| Net margin as of 2026-07-23 | -11.5% | +0.6% | DCTH higher |
| Gross margin as of 2026-07-23 | +54.6% | +86.0% | DCTH higher |
| Operating margin as of 2026-07-23 | -12.5% | -1.8% | DCTH higher |
| ROE as of 2026-07-23 | -21.0% | +0.5% | DCTH higher |
| ROA as of 2026-07-23 | -13.8% | +0.5% | DCTH higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.00 | DCTH lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.5% | +68.0% | DCTH higher |
| Revenue CAGR (3y) SEC XBRL | -2.6% | +215.3% | DCTH higher |
| Beta as of 2026-07-23 | 0.31 | 0.53 | |
| 1-year return as of 2026-07-22 close | +58.2% | +13.2% | ANGO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.